跳至主要内容
临床试验/JPRN-jRCT1080220403
JPRN-jRCT1080220403未知4 期

A Nested Case-Control Study to Determine the Relative Risk of and Risk Factors for Interstitial Lung Disease in a Cohort of NSCLC Patients Treated With and Without Gefitinib

AstraZeneca0 个研究点开始时间: 2007年6月12日最近更新:
适应症

试验速览

阶段
4 期
发起方
AstraZeneca

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • Genders Eligible for Study: Both
  • Inclusion Criteria:
  • - Advanced/recurrence NSCLC patients who have had one or more chemotherapy regimens.
  • - Patients who are to be treated with gefitinib or chemotherapy
  • - Cohort: All advanced/recurrence NSCLC patients participating in this post-marketing clinical study

排除标准

  • - Patients judged by the investigator(s) to have ILD (provisional cases) among those registered in the cohort OR Randomly selected patients without ILD (controls) for each provisional case
  • - Case-control study: Patients enrolled in the case-control study; all consenting patients with ILD as cases and approximately 4 times as many consenting patients without ILD as controls randomly selected from the cohort

研究者

发起方
AstraZeneca

相似试验